ORIGINAL ARTICLE |
|
Year : 2014 | Volume
: 62
| Issue : 6 | Page : 635--639 |
Clinical heterogeneity and a high proportion of novel mutations in a Chinese cohort of patients with dysferlinopathy
Jianying Xi1, Gaelle Blandin2, Jiahong Lu1, Sushan Luo1, Wenhua Zhu1, Christophe Beroud3, Christophe Pecheux4, Veronique Labelle4, Nicolas Levy3, Jon Andoni Urtizberea5, Chongbo Zhao1, Martin Krahn3
1 Department of Neurology, Huashan Hospital, Fudan University; Fudan University, Institute of Neurology, 200040, Shanghai, China 2 Aix Marseille University, GMGF; Inserm, UMR_S 910, 13385, Marseille, France 3 Aix Marseille University, GMGF, 13385; Inserm, UMR_S 910, 13385; Department of Medical Genetics and Cell Biology, APHM, Children's Hospital La Timone, 13385, Marseille, France 4 Department of Medical Genetics and Cell Biology, APHM, Children's Hospital La Timone, 13385, Marseille, France 5 APHP, Marin Hospital, 64700, Hendaye, France
Correspondence Address:
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0028-3886.149386
Background and Aims: Dysferlinopathies are a group of autosomal recessive muscular dystrophies caused by mutations in the dysferlin gene. This study presents clinical features and the mutational spectrum in the largest cohort of Chinese patients analyzed to date. Patients and Methods: A total of 36 unrelated Chinese patients with diagnostic suspicion of dysferlinopathy were clinically and genetically characterized. Results: Patients were divided into five phenotypes: 19 patients with limb girdle muscular dystrophy (LGMD) type 2B, 10 with Miyoshi myopathy (MM), 1 with distal anterior compartment myopathy (DACM), 3 with exercise intolerance, and 3 with asymptomatic hypercreatine phosphokinasemia (hyperCPKemia). Thirty-one patients showed an absence or drastic reduction of dysferlin expression by Westernblot. Forty-three mutations were identified in DYSF, including 31 novel. Conclusion: Our study underlines clinical heterogeneity and a high proportion of novel mutations in Chinese patients affected with dysferlinopathy.
[FULL TEXT] [PDF]*
|